Investigational New Drugs

, Volume 12, Issue 3, pp 217–222 | Cite as

A phase II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated with intravenous etoposide, methylprednisolone, high-dose arabinoside, and cisplatin as salvage therapy for relapsing and/or refractory lymphomas

  • Jorge E. Romaguera
  • M. Alma Rodriguez
  • Frederick B. Hagemeister
  • Peter McLaughlin
  • Forrest Swan
  • Dennis F. MooreJr.
  • Andreas H. Sarris
  • Anas Younes
  • Debbie Hill
  • Fernando Cabanillas
Phase II Studies
  • 27 Downloads

Summary

Purpose

To evaluate the response to oral Etoposide when combined with mesna, ifosfamide, and mitoxantrone in patients with relapsed and/or refractory lymphoma. To evaluate response and its duration after administration of intravenous Etoposide, methylprednisolone, high-dose cytosine arabinoside, and cisplatin (ESHAP) as consolidation therapy after complete or partial responses (CR or PR, respectively) or after crossover therapy for progressive disease.

Methods

Patients received MINE(o) consisting of mesna, 1.33 g/m2 infused over 1 hour daily × 3 followed 4 hours later by oral mesna at 500 mg; ifosfamide, 1.33 g/m2 infused over 1 hour daily × 3; mitoxantrone, 8 mg/m2 intravenously on day 1, and oral VP-16, 30 mg/m2 daily × 13. The ESHAP regimen consisted of intravenous VP-16, 40 mg/m2 infused over 2 hours daily × 4; methylprednisolone, 500 mg intravenously daily × 4; cytosine arabinoside, 1.5 g/m2 infused over 3 hours on day 4; and cisplatin, 25 mg/m2 given as a continuous 24-hour infusion daily × 4. Statistical analysis was performed using the 2-stage design described by Simon. For the oral VP-16 regimen to be of interest, at least 36% patients had to achieve a complete remission.

Results

The overall response rate achieved with MINE(o) was 40% (15% CR, 25% PR). Seven patients with prior exposure to cytosine arabinoside and cisplatin (AP) received MINE(o) alone of whom only one achieved a response (CR). Thirteen patients without prior exposure to AP received consolidation (2 patients) or crossover (11 patients) therapy with ESHAP. Crossover therapy with ESHAP further improved the response in only two of five patients with partial response to MINE(o) and none of six patients who failed MINE(o). Median response duration for the patients who received MINE(o)/ESHAP was 12 weeks (range, 4–55 weeks).

Conclusions

Oral VP-16 combined with ifosfamide/mesna and mitoxantrone at the doses and schedules indicated has little activity against relapsed and/or refractory lymphomas. Crossover therapy with ESHAP did not further improve the response rate. The duration of response after MINE(o)/ESHAP was short.

Key words

oral VP-16 salvage therapy lymphoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wheeler C, Strawderman M, Ayash L, Churchill WH, Bierer BE, Elias A, Gilliland DG, Antman K, Guinan EC, Eder JP, Weinstein H, Schwartz G, Ferrara J, Mazanet R, Rimm IJ, Tepler I, McCarthy P, Mauch P, Ault K, Gaynes L, Mc Cauley M, Schnipper LE, Antin J: Prognostic factors for treatment outcome in auto-transplantation of intermediate-grade and high-grade non-Hodgkin's lym-phoma with cyclophosphamide, carmustine, and etopo-side. J Clin Oncol 11:1085–1091, 1993PubMedGoogle Scholar
  2. 2.
    Cabanillas F: New chemotherapeutic agents and combinations in the treatment of lymphoma. In: Ford RJ, Fuller LM, Hagemeister FB (eds) U.T.M.D. Anderson Clinical Conference on Cancer, vol 27, Raven Press, New York, 1994, pp 391–396Google Scholar
  3. 3.
    Velasquez W, Hagemeister F, McLaughlin P, Swan F, Rodriguez MA, Romaguera J, Cabanillas F: ESHAP: an effective treatment for refractory and relapsing lymphoma: a long follow-up. (Abstract) Proc Am Soc Clin Oncol 11:326, 1992Google Scholar
  4. 4.
    Rodriguez MA, Cabanillas F, Hagemeister F, McLaughlin P, Romaguera J, Swan F, Velasquez W: MINE-ESHAP: a novel and effective salvage combination for lymphoma. (Abstract) Proc Am Soc Clin Oncol 11:327, 1992Google Scholar
  5. 5.
    Hainsworth JD, Johnson DH, Frazier SR, Greco FA: Chronic daily administration of oral etoposide-phase I trial. J Clin Oncol 7:396–401, 1989PubMedGoogle Scholar
  6. 6.
    The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Cancer 49: 2112–2135, 1982Google Scholar
  7. 7.
    Stanley KE: Prognostic factors for survival in patients with inoperable lung cancer. J Natl Can Inst 65:25–32, 1980Google Scholar
  8. 8.
    Simon R: Optimal two-stage design for phase II clinical trials. Controlled Clinical Trials 10:1–10, 1989PubMedGoogle Scholar
  9. 9.
    Clark PI, Slevin ML: The clinical pharmacology of etoposide and teniposide. Clin Pharmacokinet 12:223–252, 1987PubMedGoogle Scholar
  10. 10.
    Hainsworth JD, Johnson DH, Frazier SR, Greco FA: Chronic daily administration of oral etoposide-A phase I trial. J Clin Oncol 7:396–401, 1989PubMedGoogle Scholar
  11. 11.
    Greco FA: Future directions for etoposide therapy. Cancer 647:315–318, 1991Google Scholar
  12. 12.
    Thompson DS, Hainsworth JD, Hande KR, Holzmer MC, Greco FA: Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. J Clin Oncol 11:1322–1328, 1993PubMedGoogle Scholar
  13. 13.
    Cabanillas F: Management of the patient with relapsing or refractory lymphoma. In: Fuller LM (ed) Hodgkin's Disease and Non-Hodgkin's Lymphomas in Adults and Children. Raven Press, New York, 1988, pp 427–439Google Scholar
  14. 14.
    Segal ML, Grever MR, Ungerleider J, Balcerzak SP: Treatment of refractory non-Hodgkin's lymphoma with ifosfamide and VP-16. (Abstract) Proc Am Soc Clin Oncol 1:159, 1982Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • Jorge E. Romaguera
    • 1
  • M. Alma Rodriguez
    • 1
  • Frederick B. Hagemeister
    • 1
  • Peter McLaughlin
    • 1
  • Forrest Swan
    • 1
  • Dennis F. MooreJr.
    • 1
  • Andreas H. Sarris
    • 1
  • Anas Younes
    • 1
  • Debbie Hill
    • 1
  • Fernando Cabanillas
    • 1
  1. 1.Department of HematologyThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations